EGFR and non-small cell lung carcinoma: The pooled results demonstrated that the addition of metformin was related to better PFS in diabetic NSCLC patients receiving EGFR-TKIs (HR = 0.59, 95% CI: 0.34–1.03, p = 0.061), although the difference was not significant (Table 2).